Literature DB >> 16467127

Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats.

Hua Zhou1, Yoshihide Fujigaki, Akihiko Kato, Takehiko Miyaji, Hideo Yasuda, Takayuki Tsuji, Tatsuo Yamamoto, Katsuhiko Yonemura, Akira Hishida.   

Abstract

The purpose of this study was to evaluate whether upregulated p21, a cell cycle-inhibitory protein, contributes to cisplatin (CDDP)-induced acute renal failure (ARF) and to acquired resistance to rechallenge injury with CDDP in rats. ARF was induced in rats by injection of CDDP (5 mg/kg) and rechallenge injury to CDDP by the same dose of CDDP 14 days after the first CDDP injection. Rats were treated with p21 antisense oligodeoxynucleotide (ODN) or its vehicle, p21 sense ODN, every 36 h from days 0 to 5 for single CDDP and from days 13 to 19 for rechallenge injury and killed at day 3, 5, 16, or 19. The uptake of FITC-labeled p21 antisense ODNs by cortical proximal tubule (PT) cells was much greater than by PT cells in the outer stripe of outer medulla (OSOM). Administration of antisense induced partial downregulation of p21 mRNA and protein levels in whole kidneys with single CDDP treatment and its rechallenge injury. Antisense significantly aggravated PT necrosis and decreased the number of p21-positive PT cells in the cortex but not in the OSOM in both CDDP-induced ARF and its rechallenge injury. However, antisense did not alter serum creatinine (Scr) and blood urea nitrogen (BUN) levels. Our findings suggested that p21 plays, at least in part, a cytoprotective role in cortical PTs exposed to CDDP, although this does not contribute to renal dysfunction when judged by Scr and BUN levels. Because antisense may not adequately be taken up and/or function in PTs in the OSOM, the role of p21 in PTs in the OSOM in CDDP-induced ARF remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467127     DOI: 10.1152/ajprenal.00324.2004

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

Review 1.  Mitochondrial dysregulation and protection in cisplatin nephrotoxicity.

Authors:  Yuan Yang; Hong Liu; Fuyou Liu; Zheng Dong
Journal:  Arch Toxicol       Date:  2014-05-24       Impact factor: 5.153

Review 2.  Acute kidney injury: a springboard for progression in chronic kidney disease.

Authors:  Manjeri A Venkatachalam; Karen A Griffin; Rongpei Lan; Hui Geng; Pothana Saikumar; Anil K Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2010-03-03

Review 3.  Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy.

Authors:  Siddesh Jaiman; Arun Kumar Sharma; Kulwant Singh; Deepa Khanna
Journal:  Eur J Clin Pharmacol       Date:  2013-08-09       Impact factor: 2.953

4.  The deficiency of CX3CL1/CX3CR1 system ameliorates high fructose diet-induced kidney injury by regulating NF-κB pathways in CX3CR1-knock out mice.

Authors:  Yong-Wu Yu; Ming-Xu Li; Zhi-Yong Zhang; Hai Yu
Journal:  Int J Mol Med       Date:  2018-03-16       Impact factor: 4.101

Review 5.  Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity.

Authors:  Vladislav Volarevic; Bojana Djokovic; Marina Gazdic Jankovic; C Randall Harrell; Crissy Fellabaum; Valentin Djonov; Nebojsa Arsenijevic
Journal:  J Biomed Sci       Date:  2019-03-13       Impact factor: 8.410

Review 6.  Roles of the Skp2/p27 axis in the progression of chronic nephropathy.

Authors:  Sayuri Suzuki; Naro Ohashi; Masatoshi Kitagawa
Journal:  Cell Mol Life Sci       Date:  2012-12-20       Impact factor: 9.261

Review 7.  Pathophysiology of cisplatin-induced acute kidney injury.

Authors:  Abdullah Ozkok; Charles L Edelstein
Journal:  Biomed Res Int       Date:  2014-08-06       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.